Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …

The receptors through which serotonin (5-hydroxytryptamine, 5-HT) produces its effects
have been the subject of intense investigation, initially using both in vivo and in vitro …

As a result of controversy in the literature regarding the classification and nomenclature of
functional receptors for 5-hydroxytryptamine (5-HT), a framework for classification is …

The anatomical distribution of serotonin-2 receptors in the human brain was studied by light
microscopic autoradiography, using [3 H] ketanserin as a ligand. The receptor densities …

Recently, psychedelics have emerged as promising therapeutics for numerous
neuropsychiatric disorders. While their potential in the clinic has yet to be fully elucidated …

3. II Limitations for immunocytochemistry 3.1. 2. Receptor autoradiography artifacts 3.2.
Transmitters and receptors distributed throughout different neurons 3.2. I. Transmitter is …

In vitro and in vivo receptor-binding properties of the new serotonin antagonist, ritanserin,
are reported. In in vitro binding assays, ritanserin shows high affinity binding to serotonin-S2 …

The planned and ongoing studies of platelet function and composition should allow us to
better define the alteration which we presume to be present in platelets of autistic subjects …

A complementary DNA (cDNA) encoding a serotonin receptor with 51% sequence identity to
the 5HT‐1C subtype was isolated from a rat brain cDNA library by homology screening …

Serotonin (5hydroxytryptamine; 5-HT) was first discovered in 1948 in blood platelets and a
few years later in the brain. Since then, investigations of 5-HT involvement in mental …